We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+15.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.45B
AUM Growth
+$7.66M
Cap. Flow
-$5.91M
Cap. Flow %
-0.41%
Top 10 Hldgs %
77.82%
Holding
53
New
5
Increased
6
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$13.6M
2
VSTM icon
Verastem
VSTM
+$10.7M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$8.25M
4
DCTH icon
Delcath Systems
DCTH
+$7.39M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$7.02M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$21.7M
2
LEGN icon
Legend Biotech
LEGN
+$11.8M
3
GERN icon
Geron
GERN
+$7.85M
4
BLU
BELLUS Health Inc.
BLU
+$7.32M
5
MRUS
Merus
MRUS
+$6.51M

Sector Composition

Rank Sector Weight
1 Healthcare 99.19%
2 Materials 0.55%
3 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$615M 42.47%
5,900,000
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.06B
$91.7M 6.33%
2,606,247
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$89.8M 6.2%
4,249,918
– –
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
$63.1M 4.36%
3,829,577
+68,139
+2% +$886K
TERN
5
DELISTED
Terns Pharmaceuticals
TERN
$58.3M 4.02%
6,657,992
– –
GERN icon
6
Geron
GERN
$943M
$53M 3.66%
16,524,634
-2,758,200
-14% -$7.85M
TARS icon
7
Tarsus Pharmaceuticals
TARS
$2.57B
$40.9M 2.82%
2,262,200
– –
VRDN icon
8
Viridian Therapeutics
VRDN
$2.15B
$39.9M 2.76%
1,678,207
– –
VECT
9
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$39.4M 2.72%
2,333,300
– –
KDNY
10
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$35.9M 2.48%
934,879
+62,728
+7% +$1.61M
ALXO icon
11
ALX Oncology
ALXO
$268M
$31.7M 2.19%
4,220,048
– –
COGT icon
12
Cogent Biosciences
COGT
$6.83B
$26.6M 1.83%
2,244,941
+250,000
+13% +$2.87M
ICVX
13
DELISTED
Icosavax, Inc. Common Stock
ICVX
$16.9M 1.17%
+1,704,568
New +$13.6M
GRCL
14
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$15.1M 1.04%
3,969,427
+2,505,444
+171% +$7.02M
ATXS
15
DELISTED
Astria Therapeutics
ATXS
$14M 0.97%
1,681,199
– –
VTYX
16
DELISTED
Ventyx Biosciences
VTYX
$13.8M 0.96%
422,075
-180,000
-30% -$6.2M
ACLX
17
DELISTED
Arcellx
ACLX
$13.7M 0.95%
433,785
+143,072
+49% +$5.47M
ALLK
18
DELISTED
Allakos
ALLK
$13M 0.9%
2,988,000
-1,132,134
-27% -$5.09M
ZLAB icon
19
Zai Lab
ZLAB
$2.1B
$12.4M 0.85%
445,505
+28,865
+7% +$944K
OLMA icon
20
Olema Pharmaceuticals
OLMA
$1.01B
$12.1M 0.83%
1,339,271
-350,244
-21% -$2.11M
VSTM icon
21
Verastem
VSTM
$539M
$11.4M 0.79%
+1,538,461
New +$10.7M
CMPX icon
22
Compass Therapeutics
CMPX
$364M
$11.3M 0.78%
3,556,023
– –
ASLN
23
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$10.4M 0.72%
355,114
– –
ALPN
24
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.41M 0.65%
+914,913
New +$8.25M
ACRS icon
25
Aclaris Therapeutics
ACRS
$743M
$9.32M 0.64%
898,631
– –
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Vivo Capital held 53 positions worth $1.45B, up 0.53% from $1.44B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Vivo Capital's Q2 2023 filing shows 5 new, 6 increased, 4 reduced and 5 closed positions. Its largest new stake was Icosavax, Inc. Common Stock: 1,704,568 shares worth $16.9M. The largest sale was Vaxcyte, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Materials and Consumer Staples.

  • Vivo Capital's largest Q2 2023 buy was Icosavax, Inc. Common Stock: 1,704,568 shares worth $16.9M.
  • Vivo Capital added most to Gracell Biotechnologies Inc. American Depositary Shares in Q2 2023, an estimated $7.02M increase.
  • Vivo Capital's biggest Q2 2023 reduction was Geron, cutting an estimated $7.85M.
  • Vivo Capital fully exited Vaxcyte in Q2 2023, selling an estimated $21.7M.
  • Vivo Capital's ten largest holdings make up 78% of its $1.45B portfolio in Q2 2023.
  • Vivo Capital opened 5 new positions and closed 5 in Q2 2023.
  • Vivo Capital's portfolio value rose 0.53% quarter-over-quarter to $1.45B.

Based on Vivo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.